Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT05661552
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 108 participants
- Registry
-
NCT05661552
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05661552. Randomized; no masking; primary purpose treatment. Start 2022-12-01 (actual); primary completion 2025-02-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
- Acronym
- C-STAR
- Condition
- Low-Density-Lipoprotein-Type [LDL (LDL cholesterol)] Hyperlipoproteinemia
- Intervention (Drug)
- Evolocumab 140 MG/ML
- Intervention (Drug)
- Rosuvastatin 5mg
- Intervention (Drug)
- Ezetimibe 10mg
- Lead sponsor
- Yonsei University
- Collaborator
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct05661552- Content hash
0e575dcf41fed5a1970732512208a51d8d1cc0ac7e1fc0d92f629ec2653ade96